Dive Brief:
- Tissium, the developer of a biopolymer technology that offers a sutureless way to repair nerves, said Wednesday it has secured a financing package worth up to 60 million euros (about $68.2 million) to support its commercial rollout.
- The package consists of a 30-million-euro financing that was completed in late 2025 and a facility of up to 30 million euros from the European Investment Bank, the lending arm of the European Union.
- Tissium has obtained the funds after winning de novo authorization from the Food and Drug Administration last year for the Coaptium Connect sutureless platform in peripheral nerve repair.
Dive Insight:
Tissium is developing a family of polymers to address unmet clinical needs in tissue reconstruction.
The platform, invented by Maria Pereira, Jeffrey Karp and Robert Langer at the Massachusetts Institute of Technology and Brigham and Women’s Hospital, uses a bioresorbable light-activated surgical polymer and 3D-printed polymer chamber. Pereira is the MIT spinout’s co-founder and chief innovation officer.
The Coaptium Connect sutureless technology is Tissium’s first commercial product. In its pipeline, the company is advancing applications that include hernia repair and cardiovascular sealing. It received an investigational device exemption from the FDA in September for a clinical trial to study its Eclipsium treatment for ventral hernia repair.
The new funding will support clinical activities and expansion of the technology platform, in addition to accelerating the company’s U.S. rollout. Tissium, which has offices in Paris and Cambridge, Massachusetts, said new and existing international investors, including in the U.S., participated in the 30-million-euro Series D2 financing.
The European Investment Bank facility is available in three tranches of 10 million euros, linked to commercial, clinical and financing milestones, the company said.
The investor and bank support reflects confidence in Tissium’s technology and strategy, CEO and co-founder Christophe Bancel said in a statement.
With the Series D2 round, Tissium has raised a total of 200 million euros to date, a company spokesperson said in an email to MedTech Dive.
